Skip to the content

From Orphan Cancers to High-Value Markets with Speed and Precision

logo mainlogo darklogo light
  • About
    • Leadership Team
    • Scientific & Clinical Advisors
    • Board of Directors
    • Collaborations & Partnerships
  • Technology
  • Product Pipeline
    • EO-1001 Program
    • EO-3001 Program
    • EO-4426 Program
    • OROTECAN® Program
  • News & Media
    • Press Releases
    • Presentations & Publications
  • Contact
  • Careers
logo mainlogo darklogo light
Press Releases
Presentations & Publications
Investors

Overview

  • Press Releases
  • Presentations & Publications

Corporate Governance

  • Leadership Team
  • Scientific & Clinical Advisors

Contact

3475 Edison Way,
Suite R
Menlo Park, CA 94025

Health care researchers working in life science laboratory, medical science technology research
What's New

News & Media

Read All
Written by Edison Oncology
November 24, 2025
Press Release
Edison Oncology Presents New Clinical and Preclinical Data for EO1001 in ErbB‑Driven Tumors and EO‑4426 in CDA‑High Cancers at SNO 2025  
5 min read
Read More
Written by Edison Oncology
October 27, 2025
Press Release
Edison Oncology Presents Two Posters at the 2025 AACR-NCI-EORTC InternationalConference on Molecular Targets and CancerTherapeutics
4 min read
Read More
Written by Edison Oncology
April 8, 2024
Press Release
Edison Oncology Reports Promising Interim Data from Ongoing Orotecan® Clinical Trial for Recurrent Pediatric Cancers
4 min read
Read More

Company

  • Leadership Team
  • About
  • Careers

Information

  • Technology
  • Product Pipeline
  • Press Releases

Menlo Park, CA

  • 3475 Edison Way,
    Suite R
    Menlo Park, CA 94025

© 2025 Edison Oncology, All Rights Reserved

Back to top Drag
  • About
    • Leadership Team
    • Scientific & Clinical Advisors
    • Board of Directors
    • Collaborations & Partnerships
  • Technology
  • Product Pipeline
    • EO-1001 Program
    • EO-3001 Program
    • EO-4426 Program
    • OROTECAN® Program
  • News & Media
    • Press Releases
    • Presentations & Publications
  • Contact
  • Careers

John K. Bell

Independent Board Member

John K. Bell serves as lead independent director and chair of the audit committee.

Mr. Bell is the founder of Shred-Tech Ltd. and Polymer Technologies, Inc., John K. Bell is a businessperson who has been the head of 15 different companies and presently is Chairman at CrossChasm Technologies, Inc., Chairman & Chief Executive Officer at Onbelay Investment Corp., Chairman for Stack Capital Group, Inc., lead independent director of Edison Oncology Holding Corp., and Director & Governor at Stratford Festival. He is also on the board of Stratford Shakespearean Festival of America.

Mr. Bell was a founding investor of Research in Motion (Blackberry) and previously held the position of Director at Canopy Growth Corp. and Chairman of Canopy Rivers Corp. (a subsidiary of Canopy Growth Corp.), Chairman of Waterloo Regional Police Service, Chairman of Prosperity Council of Waterloo Region, Director at RIV Capital, Inc., Chief Executive Officer & Director at ATS Corp., Chief Executive Officer & Owner at Shred-Tech Ltd., Director at BSM Technologies, Inc., Director at BSM Technologies Ltd., Chairman of HEXO Corp., President & Chief Executive Officer of Polymer Technologies, Inc., Chairman of Cambridge Memorial Hospital, Member of Institute of Corporate Directors and Secretary & Director at Crohn’s & Colitis Foundation of Canada.

John K. Bell received an undergraduate degree from Richard Ivey School of Business.